Management of paraneoplastic neurological syndromes: Report of an EFNS Task Force

European Journal of Neurology

Volumn 13, Issue 7, 2006, Pages 682-690

  Vedeler, C A ^a,b   Antoine, J C ^c   Giometto, B ^d   Graus, F ^e   Grisold, W ^f   Hart, I K ^g   Honnorat, J ^h   Sillevis Smitt, P A E ⁱ   Verschuuren, J J G M ^j   Voltz, R ^k  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c SERVICE DE NEUROLOGIE   (France)

^d UNIVERSITY OF PADOVA   (Italy)

^e UNIVERSITY OF BARCELONA   (Spain)

^f LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^g Neuroimmunology Group   (United Kingdom)

^h HÔPITAL NEUROLOGIQUE   (France)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

Cancer; Investigation; Neurology; Paraneoplastic; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; AZATHIOPRINE; BACLOFEN; CYCLOPHOSPHAMIDE; HU ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; PROPRANOLOL; STEROID;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER THERAPY; ENCEPHALITIS; HUMAN; MEDICAL PRACTICE; MYASTHENIA GRAVIS; MYOCLONUS; NERVE STIMULATION; NEUROMUSCULAR SYNAPSE; OPSOCLONUS; ORCHIECTOMY; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; TUMOR DIAGNOSIS;

ADVISORY COMMITTEES; EUROPE; HUMANS; LAMBERT-EATON MYASTHENIC SYNDROME; LIMBIC ENCEPHALITIS; NERVOUS SYSTEM DISEASES; PARANEOPLASTIC CEREBELLAR DEGENERATION; PARANEOPLASTIC SYNDROMES; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM DISEASES; PRACTICE GUIDELINES; SOCIETIES, MEDICAL;

EID: 33746483826     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01266.x     Document Type: Review

References (73)

1. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. Journal of Neurology, Neurosurgery and Psychiatry 2004; 75: 1135-1140.
2. Willison HJ, Ang W, Gilhus NE, et al. EFNS Task force report: a questionnaire-based survey on the service provision and quality assurance for determination of diagnostic autoantibody tests in European neuroimmunology centres. European Federation of Neurological Societies. European Journal of Neurology 2000; 7: 625-628.
3. Brainin M, Barnes M, Baron J-C, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. European Journal of Neurology 2004; 11: 577-581.
4. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumor association in 50 patients. Brain 2000; 123: 1481-1494.
5. Dirr LY, Elster AD, Donofrio PD, Smith M. Evolution of brain abnormalities in limbic encephalitis. Neurology 1990; 40: 1304-1306.
6. Provenzale JM, Barboriak DP, Coleman RE. Limbic encephalitis: comparison of FDG PET and MRI findings. American Journal of Roentgenology 1998; 18: 1659-1660.
7. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127: 1831-1844.
8. Yu Z, Kryzer TJ, Grisemann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymomarelated autoimmunity. Annals of Neurology 2001; 49: 146-154.
9. Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Annals of Neurology 2001; 50: 74-79.
10. Pozo-Rosich P, Clover L, Saiz A, et al. Voltage-gated potassium channel antibodies in limbic encephalitis. Annals of Neurology 2003; 54: 530-533.
11. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of encephalitis. Brain 2004; 127: 701-712.
12. Graus F, Keime-Guibert F, Reňe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-1148.
13. Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004; 63: 282-286.
14. Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127: 2331-2338.
15. Horwich MS, Cho L, Porro RS, Posner JB. Subacute sensory neuropathy: a remote effect of carcinoma. Annals of Neurology 1977; 2: 7-19.
16. Graus F, Bonaventura I, Uchya M, et al. Indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology 1994; 44: 2258-2261.
17. Camdesssanche JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 2002; 125: 166-175.
18. Younger DS, Dalmau J, Inghirami G, et al. Anti-Hu-associated peripheral nerve and muscle microvasculitis. Neurology 1994; 44: 181-183.
19. Molinuevo JL, Graus F, Serrano C, et al. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Annals of Neurology 1998; 4: 976-980.
20. Antoine JC, Honnorat J, Camdessanche JP, et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Annals of Neurology 2001; 49: 214-221.
21. Honnorat J, Antoine JC, Derrington E, et al. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. Journal of Neurology, Neurosurgery and Psychiatry 1996; 61: 270-278.
22. Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. Journal of Neurology, Neurosurgery and Psychiatry 2000; 68: 479-482.
23. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992; 42: 1931-1937.
24. Mason WP, Graus F, Lang B, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997; 120: 1279-1300.
25. Bernal F, Shamsíli S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60: 230-234.
26. Graus F, Lang B, Pozo-Rosich P, et al. P/Q type calcium channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002; 59: 764-766.
27. Shamsíli S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126: 1409-1418.
28. Fukuda T, Motomura M, Nakao Y, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Annals of Neurology 2003; 53: 21-28.
29. Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH. Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature. Journal of Neuro-Oncology 2003; 63: 187-190.
30. Vernino S, O'Neill BP, Marks RS, et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncol 2004; 6: 55-62.
31. Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55: 713-715.
32. Anderson NE, Budde-Steffen C, Rosenblum MK, et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in adults with cancer: a distinct paraneoplastic syndrome. Medicine 1988; 67: 100-109.
33. Buttner U, Straube A, Handke V. Opsoclonus and ocular flutter. Nervenarzt 1997; 68: 633-637.
34. Straube A, Leigh RJ, Bronstein A, et al. EFNS task force-therapy of nystagmus and oscillopsia. European Journal of Neurology 2004; 11: 83-89.
35. Dropcho EJ, Kline LB, Riser J. Antineuronal (anti-Ri) antibodies in a patient with steroid-responsive opsoclonus-myoclonus. Neurology 1993; 43: 207-211.
36. Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002; 109: 86-98.
37. Gambini C, Conte M, Bernini G, et al. Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Archiv 2003; 442: 555-562.
38. Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124: 437-443.
39. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurology 2002; 1: 294-305.
40. Darnell JC, Posner JB. Paraneoplastic syndromes involving the nervous system. New England Journal of Medicine 2003; 349: 1543-1554.
41. Berger JR, Mehari E. Paraneoplastic opsoclonus-myoclonus secondary to malignant melanoma. Journal of Neuro-Oncology 1999; 41: 43-45.
42. Zamecnik J, Cerny R, Bartos A, et al. Paraneoplastic opsoclonus-myoclonus syndrome associated with malignant fibrous histiocytoma: neuropathological findings. Ceskoslovenska Patologie 2004; 40: 63-67.
43. Antunes NL, Khakoo Y, Matthay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. Journal of Pediatric Hematology/oncology 2000; 22: 315-320.
44. Pranzatelli MR, Tate ED, Wheeler A, et al. Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatric Neurology 2002; 27: 384-387.
45. Bataller L, Rosenfeld MR, Graus F, et al. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Annals of Neurology 2003; 53: 347-353.
46. Prestigiacomo CJ, Balmaceda C, Dalmau J. Anti-Ri-associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinoma. Cancer 2001; 91: 1423-1428.
47. Wong AM, Musallam S, Tomlinson RD, et al. Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. Journal of the Neurological Sciences 2001; 189: 71-81.
48. Wirtz PW, Sillevis Smitt PA, Hoff JI, et al. Anti-Ri antibody positive opsoclonus-myoclonus in a male patient with breast carcinoma. Journal of Neurology 2002; 249: 1710-1712.
49. Swart JF, de Kraker J, van der Lely N. Meta-iodobenzylguanidine total-body scintigraphy required for revealing occult neuroblastoma in opsoclonus-myoclonus syndrome. European Journal of Pediatrics 2002; 161: 255-258.
50. Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. Journal of Pediatrics 2001; 139: 552-559.
51. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Medical and Pediatric Oncology 2001; 36: 612-622.
52. Jongen JL, Moll WJ, Sillevis Smitt PA, et al. Anti-Ri positive opsoclonus-myoclonus-ataxia in ovarian duct cancer. Journal of Neurology 1988; 245: 691-692.
53. Nitschke M, Hochberg F, Dropcho E. Improvement of paraneoplastic opsoclonus-myoclonus after protein A column therapy. New England Journal of Medicine 1995; 332: 192.
54. Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery and Psychiatry 2002; 73: 766-768.
55. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988; 111: 577-596.
56. Motomura M, Johnston I, Lang B, et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery and Psychiatry 1995; 58: 85-87.
57. Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. Journal of Neuroimmunology 2005; 159: 230-237.
58. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990; 40: 1552-1556.
59. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999; 353: 117-118.
60. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. New England Journal of Medicine 1989; 321: 1567-1571.
61. Hart IK, Waters C, Vincent A, et al. Autoantibodies detected to expressed potassium channels are implicated in neuromyotonia. Annals of Neurology 1997; 41: 238-246.
62. Hart IK, Maddison P, Newsom-Davis J, et al. Phenotypic variants of peripheral nerve hyperexcitability. Brain 2002; 125: 1887-1895.
63. Caress JB, Abend WK, Preston DC, Logigian EL. A case of Hodgkin's lymphoma producing neuromyotonia. Neurology 1997; 49: 258-259.
64. Lahrmann H, Albrecht G, Drlicek M, et al. Acquired neuromyotonia and peripheral neuropathy in a patient with Hodgkin's disease. Muscle and Nerve 2001; 24: 834-838.
65. Zifko U, Drlicek M, Machacek E, et al. Syndrome of continuous muscle fiber activity and plasmacytoma with IgM paraproteinemia. Neurology 1994; 44: 560-561.
66. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 1993; 116: 453-469.
67. Toepfer M, Schroeder M, Unger JM, et al. Neuromyotonia, myoclonus, sensory neuropathy and cerebellar symptoms in a patient with antibodies to neuronal nucleoproteins (anti-Hu-antibodies). Clinical Neurology and Neurosurgery 1999; 101: 207-209.
68. Hayat GR, Kulkantrakorn K, Campbell WW, Giuliani MJ. Neuromyotonia: autoimmune pathogenesis and response to immune modulating therapy. Journal of the Neurological Sciences 2000; 181: 38-43.
69. + channels of peripheral nerves. Annals of Neurology 1995; 38: 714-722.
70. Alessi G, De Reuck J, De Bleecker J, Vancayzeele S. Successful immunoglobulin treatment in a patient with neuromyotonia. Clinical Neurology and Neurosurgery 2000; 102: 173-175.
71. Ishii A, Hayashi A, Ohkoshi N, et al. Clinical evaluation of plasma exchange and high dose intravenous immunoglobulin in a patient with Isaacs' syndrome. Journal of Neurology, Neurosurgergy, and Psychiatry 1994; 57: 840-842.
72. van den Berg JS, van Engelen BG, Boerman RH, de Baets MH. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. Journal of Neurology 1999; 246: 623-625.
73. Nakatsuji Y, Kaido M, Sugai F, et al. Isaacs' syndrome successfully treated by immunoadsorption plasmapheresis. Acta Neurologica Scandinavica 2000; 102: 271-273.